Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,404 across all filing types
Latest filing 2018-10-24 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-10-24 English
ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATION
Regulatory Filings
2018-10-23 English
AstraZeneca Extends Innate Pharma Collaboration
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 8273E' and is dated October 23, 2018. It details a significant business development: an expanded collaboration and transaction between AstraZeneca and Innate Pharma concerning oncology assets (monalizumab, IPH5201, Lumoxiti) and an equity stake purchase. This type of announcement, which details corporate transactions, partnerships, and financial considerations outside of standard periodic financial reports (like 10-K or IR), is typically disseminated via regulatory news services. The presence of the RNS number strongly indicates it is a regulatory announcement. Since it is a specific corporate action announcement rather than a general update or a report itself, it fits best under the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard disclosures, although it could also be argued as a 'Capital/Financing Update' (CAP) due to the equity stake purchase. However, the primary nature is a broad business/collaboration update disseminated via RNS. Given the options, RNS is the most appropriate general classification for a document explicitly marked as an RNS release detailing corporate activity.
2018-10-23 English
LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCER
Regulatory Filings
2018-10-22 English
Lynparza shows 70% reduction in PFS ovarian cancer
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content details clinical trial results (SOLO-1 trial for Lynparza) and includes quotes from company executives and medical professionals, along with links to associated PDF documents and references to publications (NEJM, ESMO Congress). This structure—a press release format announcing significant corporate/clinical news via an official regulatory channel—is characteristic of a general regulatory filing or announcement that doesn't fit the more specific categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). Since it is a formal announcement distributed through RNS, and it is not a specific report type like a dividend notice (DIV) or a proxy statement (DEF 14A), the most appropriate classification is the general regulatory filing category, RNS.
2018-10-22 English
CHMP positive opinion Bevespi Aerosphere
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 6420E' and concludes with a statement that 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory news service announcement. The content is a press release announcing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding a drug (Bevespi Aerosphere). This type of announcement, which is a general regulatory update that doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or DIV), is best classified under the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous regulatory announcements.
2018-10-19 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.